RAPP Research | Milton Maxwell

RAPP

Rapport Therapeutics, Inc.

30.76

+1.16+3.92%

Dec 16, 4:00:01 PM EST

Upcoming Earnings

Report date

≈ -/-

Earnings Call Transcripts

This Quarter (Q1 '26)

No earnings call transcript available yet

Last Quarter (Q4 '25)

No earnings call transcript available

Key Stats

Market Cap

1.47B

P/E (TTM)

Basic EPS (TTM)

-2.27

Dividend Yield

Recent Filings

8-K

Q4 2025 results, RAP-219 advances

3/10/26Mar 10, 2026

Rapport Therapeutics posted a $111.5M net loss for 2025, up from $78.3M in 2024, driven by $94.8M R&D spend amid pipeline acceleration. RAP-219's Phase 2a in focal onset seizures hit 77.8% median seizure reduction; Phase 3 starts Q2 2026. Cash at $490.5M funds ops into H2 2029. Tenacia deal nets $20M upfront for Greater China rights.

10-K

FY2025 results

3/10/26Mar 10, 2026

Rapport Therapeutics posted FY2025 ended December 31, 2025 results reflecting clinical-stage biotech norms: significant losses from R&D on RAP-219 and discovery programs, with no revenue disclosed in the 10-K. Q4 momentum surged with positive Phase 2a topline in drug-resistant focal onset seizures (announced September 2025), rapid onset efficacy across both 4-week segments, FDA end-of-Phase 2 clearance (December 2025), and Phase 3 initiation set for Q2 2026. Open-label safety data due H2 2026; bipolar mania Phase 2 enrolling, PGTCS Phase 3 eyed H1 2027. Cash position supports runway, but funding needs loom. Clinical trials may fail to replicate early data.

8-K

RAP-219 Phase 3 accelerated

1/7/26Jan 7, 2026

Rapport Therapeutics accelerates RAP-219 Phase 3 initiation in focal onset seizures to Q2 2026 after FDA clearance, backed by robust Phase 2a data. Epilepsy portfolio expands to primary generalized tonic-clonic seizures with Phase 3 planned for 1H 2027; bipolar mania Phase 2 stays on track for 1H 2027 topline. Cash funds operations into 2H 2029. Pipeline prioritizes high-impact programs.

8-K

Files $110M stock prospectus

1/7/26Jan 7, 2026

Rapport Therapeutics filed a prospectus supplement on January 7, 2026, registering up to $110 million in common stock sales through sales agents Leerink Partners and Cantor Fitzgerald under its July 1, 2025 agreement. No sales have occurred yet. This bolsters cash reserves for biotech needs.

8-K

RAP-219 Phase 2a succeeds

11/6/25Nov 6, 2025

Rapport Therapeutics reported positive Phase 2a topline results for RAP-219 in drug-resistant focal onset seizures, with 77.8% median clinical seizure reduction and 24% seizure freedom over 8 weeks. Cash swelled to $513.0 million post-$269.4 million offering, funding operations into H2 2029 while advancing Phase 3 trials in 2026. Bipolar mania Phase 2 stays on track for 2027 data.

About

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is based in Boston, Massachusetts.

CEO

Dr. Steven M. Paul M.D.

IPO

6/7/2024

Website

https://www.rapportrx.com

Employees

Sector

Healthcare

Industry

Biotechnology